Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Undecimal Bio has closed an oversubscribed Seed financing round of $18 million. The funding will be used to expand its AI-enabled platform for targeted siRNA therapeutic delivery.
Amount Raised
$18 Million
Round Type
Seed
Description
Undecimal Bio, a spin-out from Eleven Therapeutics, announced the launch of its platform biotechnology company with an $18 million seed financing. The funding is aimed at enhancing DELiveri®, its proprietary platform that targets RNA medicines to specific cell types. This innovation seeks to address significant challenges in genetic medicine delivery. The oversubscribed round highlights strong investor interest in advancing siRNA therapeutics.
Fundz sees it the moment Undecimal Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Undecimal Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.